Uveal Neoplasms Market Report 2026

Uveal Neoplasms Market Overview

• Uveal Neoplasms market size has reached to $1.14 billion in 2025 • Expected to grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Rising Incidence Of Eye Cancer And Its Impact On The Market • Market Trend: New Systemic Therapy Approval Expands Treatment Options for Uveal Melanoma • North America was the largest region in 2025.

What Is Covered Under Uveal Neoplasms Market?

Uveal neoplasms are tumors that develop in the uveal tract of the eye, which includes the iris, ciliary body, and choroid. They can be benign (nevus) or malignant (uveal melanoma), affecting vision and potentially spreading to other organs. The main treatment types of uveal neoplasms are drugs and therapy. Uveal neoplasms drugs refer to medications used to treat tumors or cancerous growths that develop in the uveal tract of the eye, which includes the iris, ciliary body, and choroid. These drugs are administered through various routes, including oral, injectable, and others, and are distributed through multiple channels, such as hospital pharmacies, online pharmacies, and retail pharmacies.

What Is The Uveal Neoplasms Market Growth Forecast?

The uveal neoplasms market size is expected to see strong growth in the next few years. It will grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine in ophthalmology, rising investment in ocular oncology research, expansion of immunotherapy applications, growing demand for minimally invasive eye treatments, increasing use of advanced imaging diagnostics. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced ocular imaging technologies, growing focus on early tumor detection, expansion of personalized treatment regimens, enhanced integration of multidisciplinary eye care.

What Is The Driver Of The Uveal Neoplasms Market?

The rising incidence of eye cancer is expected to propel the growth of the uveal neoplasms market going forward. Eye cancer refers to the growth of abnormal cells in the eye, which can occur in various parts of the eye, such as the retina, iris, or optic nerve. The rising incidence of eye cancer may be attributed to factors such as increased detection, environmental exposures, and aging populations. Uveal neoplasms, particularly uveal melanoma, are a rare form of eye cancer that can metastasize to other organs, notably the liver, posing significant health risks. For instance, in 2023, according to Cancer Research UK, a UK-based cancer research organization, eye cancer incidence rates are projected to rise by 50% in the UK between 2023-2025 and 2038-2040, to 3 cases per 100,000 people on average each year by 2038. Therefore, the rising incidence of eye cancer is driving the growth of the uveal neoplasms industry.

Key Players In The Global Uveal Neoplasms Market

Major companies operating in the uveal neoplasms market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., IDEAYA Biosciences Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Verastem Oncology Inc., Iovance Biotherapeutics Inc., Immunocore Holdings PLC, Aura Biosciences, Foghorn Therapeutics Inc., Syncona Limited, iOnctura SA, Linnaeus Therapeutics, Inc., Delcath Systems Inc, Bellicum Pharmaceuticals Inc.

Global Uveal Neoplasms Market Trends and Insights

Major companies operating in the uveal neoplasms market are focusing on incorporating advanced liver-directed treatment approaches such as percutaneous hepatic perfusion (PHP) to enhance localized tumour control and reduce systemic toxicity. Percutaneous hepatic perfusion (PHP) is a minimally invasive technique that isolates the liver’s blood supply to deliver high-dose chemotherapy directly into the hepatic artery while filtering the blood exiting the liver, enabling concentrated treatment at the tumour site with reduced exposure to the rest of the body. For instance, in August 2023, Delcath Systems, Inc., a US-based interventional oncology company, received U.S. Food and Drug Administration (FDA) approval for HEPZATO KIT, a PHP-based therapy for treating metastatic uveal melanoma with unresectable liver-dominant metastases, featuring targeted melphalan infusion and extracorporeal filtration of hepatic blood with treatment cycles typically repeated every 6–8 weeks as clinically appropriate. HEPZATO KIT enables higher local drug concentration with reduced systemic exposure and has shown clinically meaningful benefits, including tumour response and disease control in eligible metastatic uveal melanoma patients.

What Are Latest Mergers And Acquisitions In The Uveal Neoplasms Market?

In August 2023, TriSalus Life Sciences, a US-based oncology company, merged with MedTech Acquisition Corporation for an undisclosed amount. This merger seeks to strengthen TriSalus' platform, enhancing treatments for liver and pancreatic including uveal melanoma with liver metastases cancer patients. It is expected to accelerate technology development and drive sales growth while securing funding for key initiatives through mid-2024. MedTech Acquisition Corporation operates a US-based special purpose acquisition company (SPAC) focused on merging with businesses in the medical technology sector.

What Defines the Uveal Neoplasms Market?

The uveal neoplasms market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The uveal neoplasms market also includes sales of diagnostic equipment, therapies, and pharmaceuticals. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Uveal Neoplasms Market Report 2026?

The uveal neoplasms market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the uveal neoplasms industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.